Addiction

Addiction Therapeutics is a biotechnology company dedicated to developing novel pharmacological treatments for substance use disorders, including opioid, alcohol, and cocaine addiction. The company focuses on targeting neurobiological pathways involved in dependence, such as the metabotropic glutamate receptor 5 (mGluR5), to reduce cravings and prevent relapse. By leveraging advancements in neuroscience, Addiction Therapeutics aims to provide more effective and accessible options for patients struggling with chronic addiction. Their research and development efforts are centered on creating small molecule therapies that address the underlying chemical imbalances in the brain associated with addictive behaviors.